Aβ-Protein Inhibitors Reshaping Alzheimer’s Disease Treatment and Drug Development

The Evolving Alzheimer’s Disease Treatment Landscape

Alzheimer’s disease treatment is undergoing a significant transformation as research increasingly moves beyond symptom management toward therapies designed to address underlying disease mechanisms. For many years, available treatments primarily focused on temporarily improving or maintaining cognitive and behavioral symptoms. However, advances in biomarker research, molecular biology, and drug development have created opportunities to intervene more directly in the biological processes associated with disease progression.

One of the most important developments has been the emergence of therapies targeting amyloid-beta (Aβ), a protein that can accumulate in the brain and form plaques associated with Alzheimer’s pathology. The development of amyloid beta inhibitors has provided clinical evidence supporting the potential of amyloid-directed treatment to modestly slow cognitive and functional decline in appropriately selected individuals with early-stage disease.

This shift has made amyloid targeting an important component of modern Alzheimer’s drug development. At the same time, researchers are working to improve treatment effectiveness, safety, patient selection, administration methods, and the ability of therapies to reach relevant targets within the brain.

The Growing Role of Aβ Protein Inhibitors in Alzheimer’s Disease

The emergence of Aβ protein inhibitors represents a major development in the evolution of disease-modifying Alzheimer’s therapies. Rather than simply addressing symptoms, these therapies are designed to interact with specific forms of amyloid-beta involved in the disease process.

According to DelveInsight, LEQEMBI (lecanemab) and KISUNLA (donanemab) are two Aβ-targeting therapies with full regulatory approval for early Alzheimer’s disease in the United States. Their development and clinical use have established an important benchmark for the broader field and have demonstrated how biomarker-guided treatment can become increasingly relevant to Alzheimer’s disease management.

Lecanemab targets soluble amyloid protofibrils, forms of amyloid believed to contribute to disease pathology. In clinical development, the therapy demonstrated a statistically significant slowing of clinical decline in a Phase III study. Its development has also extended beyond intravenous administration, with LEQEMBI IQLIK offering a subcutaneous maintenance formulation intended to provide an alternative and potentially more convenient administration option.

Donanemab takes a somewhat different approach by targeting a pyroglutamate form of amyloid-beta associated with established plaques. Its treatment strategy includes the possibility of discontinuing treatment after sufficient amyloid plaque clearance has been confirmed. Such approaches highlight the industry's broader effort to develop treatment strategies that are not only biologically effective but also practical for long-term patient care.

Approved Therapies Are Influencing the Next Generation of Development

The clinical progress of approved amyloid-targeting therapies is influencing the direction of the wider Alzheimer’s drug development pipeline. Developers are exploring different antibody structures, targets, routes of administration, and mechanisms for improving drug delivery to the brain.

One notable candidate is trontinemab, which is being developed using Roche’s Brain Shuttle technology. The approach is intended to improve the delivery of therapeutic antibodies across the blood-brain barrier, one of the longstanding challenges in central nervous system drug development. Better brain delivery could potentially allow future therapies to achieve meaningful target engagement while addressing some of the limitations associated with conventional antibody approaches.

Another emerging candidate is remternetug, which is being investigated as a potentially more convenient subcutaneous successor to donanemab. The development of subcutaneous therapies reflects increasing attention toward administration convenience, treatment burden, and the practical requirements of long-term Alzheimer’s disease management.

Beyond antibody-based therapies, researchers are also evaluating small molecules and approaches designed to target specific amyloid species. Valiltramiprosate, also known as ALZ-801, is an oral small-molecule therapy being investigated for its ability to inhibit amyloid oligomer formation. An oral treatment option could represent an important alternative to infusion-based approaches if clinical development successfully demonstrates meaningful benefits.

Sabirnetug, or ACU193, represents another targeted strategy. The candidate selectively targets soluble amyloid-beta oligomers, reflecting the growing interest in identifying specific amyloid forms that may play important roles in disease progression.

Expanding the Alzheimer’s Drug Development Pipeline

The Alzheimer’s drug development pipeline extends beyond the currently approved therapies and includes a broad range of candidates designed to address different challenges associated with amyloid-targeted treatment. Programs such as PRI-002, PRX012, PMN310, and TML-6 demonstrate continued efforts to refine the therapeutic approach.

These candidates reflect several major development priorities within the field. Researchers are seeking to improve target selectivity, increase treatment convenience, enhance brain penetration, reduce potential safety concerns, and develop therapies that can be administered more easily over extended treatment periods.

PRX012, for example, represents continued interest in next-generation antibody approaches, while PMN310 is being investigated with a focus on soluble amyloid-beta oligomers. PRI-002 represents another approach centered on amyloid aggregation, demonstrating that the field continues to investigate different points within the amyloid pathway rather than relying on a single therapeutic mechanism.

The continued diversification of the pipeline is important because Alzheimer’s disease is biologically complex. Amyloid accumulation represents only one component of the disease process, and researchers are simultaneously investigating tau pathology, neuroinflammation, synaptic dysfunction, neuronal damage, and other mechanisms. Consequently, future treatment strategies may increasingly involve combinations or sequential approaches targeting multiple disease pathways.

Market Growth and Increasing Demand for Disease-Modifying Therapies

The evolution of Alzheimer’s treatment is also influencing the broader commercial landscape. According to DelveInsight, the Alzheimer’s disease market across the seven major markets, comprising the United States, EU4, the United Kingdom, and Japan, was valued at nearly USD 4 billion in 2025. The market is projected to expand at a 22.7% CAGR through 2036.

Several factors are expected to contribute to this growth. The introduction and adoption of disease-modifying therapies are creating new treatment opportunities for eligible patients, while improvements in diagnostic technologies can support earlier identification of individuals with Alzheimer’s pathology.

Earlier diagnosis is particularly relevant to amyloid-targeting therapies because clinical development has primarily focused on patients in the early stages of disease. Greater use of biomarkers and diagnostic assessments may therefore play an increasingly important role in determining which patients are appropriate candidates for disease-modifying treatment.